T1	p 173 238	patients with chronic heart failure after myocardial infarction .
T2	p 373 409	patients with heart failure ( HF ) .
T3	p 575 637	patients with class II to IV HF and ejection fraction < 35 % .
T4	p 1481 1535	HF patients with chronic postinfarction cardiomyopathy
T5	p 1849 1895	HF patients with postinfarction cardiomyopathy
T6	i 152 169	catheter delivery
T7	i 312 341	transcatheter intramyocardial
T8	i 360 369	myoblasts
T9	i 418 424	MARVEL
T10	i 441 459	placebo-controlled
T11	i 469 571	image-guided , catheter-based intramyocardial injection of placebo or myoblasts ( 400 or 800 million )
T12	i 994 1001	placebo
T13	i 1100 1110	amiodarone
T14	i 1164 1171	placebo
T15	i 1354 1361	placebo
T16	o 81 114	safety and cardiovascular effects
T17	o 662 790	frequency of serious adverse events ( safety ) and changes in 6-minute walk test and Minnesota Living With HF score ( efficacy )
T18	o 947 964	numbers of events
T19	o 1053 1085	deaths . Ventricular tachycardia
T20	o 1245 1264	functional capacity
T21	o 1432 1463	Minnesota Living With HF scores